ID Practice Update

Hepatitis B and C

Workup, test interpretation, treatment, immunosuppression planning, and follow-up

Resident core 40–45 minutes. Optional fellow-level extension follows. Edited November 10, 2026.

Advanced fellow teaching is below

The core lecture comes first. The advanced section covers discordant HBV testing, reactivation risk, treatment withdrawal, and complex HCV care.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

1. What should learners be able to do?

RESIDENT

  • Interpret HBsAg, anti-HBs, total anti-HBc, and IgM anti-HBc without calling every positive IgM result acute infection.
  • Complete the initial evaluation of HBsAg-positive patients, including fibrosis staging, coinfection testing, and HCC risk assessment.
  • Explain how disease phase, fibrosis, and patient factors influence HBV treatment eligibility and the choice among entecavir, tenofovir alafenamide, and tenofovir disoproxil fumarate.
  • Screen before immunosuppression and distinguish patients who need prophylaxis from those who may be monitored.
  • Distinguish active HCV from a persistent antibody result, identify the population for simplified treatment, and explain how cure is documented.

FELLOW

  • Resolve isolated core antibody, discordant serologies, possible occult HBV, and indeterminate chronic HBV.
  • Compare HBV reactivation risk during B-cell depletion, CAR-T therapy, stem-cell transplantation, checkpoint inhibition, prolonged corticosteroid exposure, and HCV treatment.
  • Know when simplified HCV treatment does not apply and when a protease inhibitor is unsafe.

2. Start HBV evaluation with the triple panel

RESIDENT

CDC recommends a hepatitis B triple panel at least once for all adults aged 18 or older. Check HBsAg during each pregnancy, preferably in the first trimester, even after vaccination or prior testing. Susceptible patients with ongoing exposure risk may need repeat testing.

Order HBsAg, anti-HBs, and total anti-HBc together. Add IgM anti-HBc when acute infection is clinically plausible. HBV DNA is not part of routine population screening, but it is essential once current infection, occult infection, or reactivation risk is suspected.
HBsAgTotal anti-HBcAnti-HBsLikely interpretationNext step
−−−Susceptible if no documented complete vaccine seriesVaccinate. Do not delay vaccination while awaiting results if testing and vaccination can occur at the same visit.
−−+Vaccine-associated anti-HBs; confirm a completed series and exclude recent passive antibodyNo routine booster for immunocompetent adults with a documented series. Special rules apply to dialysis, occupational exposure, and selected immunocompromised patients.
−++Resolved natural infectionNo chronic-HBV treatment. Document reactivation risk before future immunosuppression.
++−Current infectionUse IgM anti-HBc, history, and persistence of HBsAg to distinguish acute from chronic. Obtain HBV DNA, ALT, HBeAg/anti-HBe, and stage liver disease.
−+−Isolated core antibodyCould be remote resolved infection with waned anti-HBs, false-positive anti-HBc, window-period acute infection, or occult HBV. See the advanced section.
+++Discordant but possibleRepeat on a new specimen, confirm HBsAg if the assay permits, and obtain HBV DNA. Consider assay interference, recent HBIG, subtype-mismatched antibody, or surface-gene variants; see the advanced discussion.
Two common traps: HBsAg may be transiently positive shortly after hepatitis B vaccination. IgM anti-HBc can also be positive during a severe flare or reactivation of chronic HBV, so it is not proof of a new acute infection by itself.

Acute versus chronic HBV

Acute infection is supported by
Compatible exposure and hepatitis syndrome, HBsAg positivity, and IgM anti-HBc positivity. During the window period, HBsAg may already be negative while IgM anti-HBc remains positive.
Chronic infection is established by
HBsAg persisting for at least 6 months, or prior evidence of chronic infection. A single HBsAg-positive result without earlier testing does not date the infection.

3. Complete the HBV workup before deciding to treat

RESIDENT

Define viral activity. Quantitative HBV DNA, HBeAg, anti-HBe, ALT, AST, bilirubin, albumin, alkaline phosphatase, and INR.
Stage liver disease. CBC/platelets, FIB-4, and preferably elastography when available. Review imaging for nodularity, splenomegaly, collaterals, or ascites. Biopsy is reserved for cases in which noninvasive assessment and laboratory findings do not settle a treatment decision.
Look for coinfection. HIV Ag/Ab, HCV antibody with reflex RNA, and anti-HDV with reflex HDV RNA if positive. EASL 2025 recommends at least one anti-HDV test for every HBsAg-positive patient; the AASLD 2018 guidance uses risk-based testing. This module follows the EASL screening approach. Repeat testing when exposure risk continues or otherwise unexplained hepatitis develops.
Identify preventable liver injury. Check HAV immunity and vaccinate if nonimmune. Assess alcohol, metabolic dysfunction/steatotic liver disease, medications and supplements, and iron overload or autoimmune liver disease when the pattern warrants it.
Plan drug safety. Creatinine/estimated creatinine clearance and urine protein/glucose before tenofovir; add serum phosphorus in chronic kidney disease. Review osteoporosis, fragility fracture, pregnancy potential, and prior lamivudine exposure.
Address transmission. Test and vaccinate household and sexual contacts. Counsel on blood exposure, barrier protection until partner immunity is documented, and avoiding shared razors, toothbrushes, or injection equipment.

Who needs HCC surveillance?

Use liver ultrasound plus AFP approximately every 6 months when surveillance is indicated. This includes Child-Pugh A or B HBV cirrhosis and transplant-eligible Child-Pugh C disease and selected noncirrhotic patients at increased risk, including men from endemic countries older than 40, women from endemic countries older than 50, people from Africa at an earlier age, those with a first-degree family history of HCC, and patients with PAGE-B ≥10 (validated chiefly in patients receiving antiviral therapy). The 2025 AASLD/IDSA guidance also includes adults with active HBV/HDV coinfection and, without cirrhosis, HBV/HIV coinfection in men age 18 or older and women age 40 or older. Anti-HDV positivity without detectable HDV RNA follows the HBV-alone surveillance criteria. Surveillance assumes the patient could benefit from HCC treatment; competing illness and transplant candidacy affect that judgment.

Do not use normal ALT or suppressed HBV DNA to cancel HCC surveillance. Antiviral therapy reduces but does not eliminate HCC risk.

4. HBV phase and host factors shape treatment

RESIDENT

These are adult treatment principles using the AASLD/IDSA 2025 guideline and the AASLD 2018 guidance for questions not replaced by that update. Other societies use different eligibility thresholds.

Clinical settingTreatment rationale and boundaries
Acute liver failure or severe/protracted acute hepatitis BThese are indications for prompt high-barrier nucleos(t)ide therapy and urgent hepatology/transplant assessment. Uncomplicated acute HBV usually receives supportive care.
HBsAg-positive cirrhosisAntiviral therapy is indicated regardless of HBV DNA or ALT in this AASLD framework. Decompensated disease generally requires indefinite nucleos(t)ide therapy with hepatology/transplant care; peginterferon is contraindicated.
HBeAg-positive immune-active CHBHBV DNA ≥20,000 IU/mL together with ALT ≥2 times the HBV-specific ULN defines the usual immune-active treatment population. Significant inflammation or fibrosis also informs treatment when the laboratory pattern is incomplete.
HBeAg-negative immune-active CHBHBV DNA ≥2,000 IU/mL together with ALT ≥2 times the HBV-specific ULN defines the usual immune-active treatment population. Significant inflammation or fibrosis also informs treatment when the laboratory pattern is incomplete.
Immune-tolerant CHB2025 AASLD conditionally suggests treatment when age is over 40 or there is at least F2 fibrosis or grade 2 inflammation; evidence certainty is very low. The immune-tolerant pattern requires HBeAg positivity, HBV DNA >10 million IU/mL, and normal ALT on at least two measurements over at least 6 months.
HBeAg-negative indeterminate CHBTreatment is conditionally supported through shared decision-making, with very-low-certainty evidence. Fibrosis, age, sex, platelet count, family history of HCC, and persistent ALT/HBV DNA abnormalities influence the balance. Elevated ALT with low HBV DNA also raises the possibility of another cause of liver injury.
Pregnancy with HBV DNA >200,000 IU/mLAASLD/IDSA recommends TDF or TAF to reduce perinatal transmission, usually starting at gestational week 28 or promptly if first evaluated later. If infant HBIG will be unavailable, the guideline advises starting at week 16 with subsequent infant vaccination. Consider earlier prophylaxis when preterm delivery risk is high or when amniocentesis is planned and HBV DNA exceeds 2,000,000 IU/mL. TDF has the longer pregnancy safety record. The usual infant pathway includes HBV vaccine and HBIG within 12 hours of birth, completion of vaccination, and HBsAg/anti-HBs testing at age 9–12 months or 1–2 months after a delayed series is completed.
Immunosuppression or high-risk transmission settingTreatment or prophylaxis may be indicated even when ordinary disease-activity thresholds are not met.

AASLD uses HBV-specific ALT upper limits of 25 U/L for women and 35 U/L for men. Laboratory reference ranges may be higher.

Stopping at delivery is an option when antiviral therapy was used solely for perinatal prevention. Ongoing maternal HBV disease can justify continued treatment. After withdrawal, ALT and HBV DNA monitoring every 1–3 months for 6 months addresses the risk of a postpartum flare. A significant withdrawal flare, including ALT ≥5 times ULN, requires prompt reassessment and antiviral reinitiation.

Preferred nucleos(t)ide agents and a selected interferon option

AgentRole and selectionImportant limitations and monitoring
Entecavir (Baraclude)High barrier to resistance in nucleoside-naive patients; useful when renal or bone toxicity is a concernFasting administration and renal clearance affect exposure. Creatinine clearance <50 mL/min, including dialysis, requires dose or interval adjustment. In HIV coinfection it must accompany fully suppressive ART. Prior lamivudine resistance reduces its resistance barrier; tenofovir is generally favored in that setting.
Tenofovir alafenamide (Vemlidy for HBV)Potent; smaller declines in estimated creatinine clearance and bone mineral density than TDF in trials; long-term clinical benefit from those differences is uncertainAdministration requires food. Renal monitoring includes creatinine/estimated clearance and urine protein/glucose, with phosphorus in CKD. Labeling does not recommend use at creatinine clearance <15 mL/min without chronic hemodialysis, or in Child-Pugh B/C disease. Dialysis affects administration timing. HIV status and P-gp interactions also affect selection.
Tenofovir disoproxil fumarate (Viread)Potent, high barrier; extensive pregnancy experience. In HIV/HBV coinfection, the usual regimen includes TDF or TAF with FTC or 3TC within fully suppressive ART, selected for renal, bone, and interaction risks (NIH HBV/HIV guidance, September 2026)Renal clearance determines dosing interval when creatinine clearance is <50 mL/min; no labeled dose is established below 10 mL/min without hemodialysis. Follow-up includes creatinine/estimated clearance, urine protein/glucose, phosphorus in CKD, and bone assessment when indicated. Concurrent or recent nephrotoxic drugs increase concern for renal injury.
Peginterferon alfa-2a (Pegasys)Finite course in selected noncirrhotic patients who accept toxicity and have favorable predictorsSubcutaneous therapy; avoid in pregnancy, uncontrolled psychiatric illness, and significant cytopenias. Autoimmune hepatitis and hepatic decompensation are contraindications. Severe renal impairment, including creatinine clearance <30 mL/min, changes dose selection. Close CBC, hepatic, thyroid, and clinical monitoring plus baseline eye assessment are part of treatment.

Formulation-specific dosing and interaction details are available in the entecavir, TAF, TDF, and peginterferon prescribing information.

Resistance and toxicity limit older HBV agents. Lamivudine, adefovir, and telbivudine are not preferred for routine long-term initial therapy when entecavir, TAF, or TDF is suitable.

5. HBV follow-up depends on phase and treatment status

RESIDENT

Patient groupPractical follow-up
Immune-tolerant, untreatedALT and HBV DNA every 6 months; reassess fibrosis and treatment need at each visit.
HBeAg-positive indeterminate, untreatedALT and HBV DNA every 3–6 months when near an immune-active transition; otherwise every 6 months. Reassess fibrosis.
Inactive CHB, HBeAg negative, DNA <2,000, normal ALTALT and HBV DNA every 3 months for the first year to establish inactivity, then every 6–12 months if stable. Recheck sooner if ALT rises; assess HBsAg loss annually.
HBeAg-negative indeterminate, untreatedUsually ALT and HBV DNA every 3–6 months for the first year, then every 6 months; revisit treatment rather than leaving the patient indefinitely in a “gray zone.”
Receiving entecavir, TAF, or TDFAssess adherence, ALT, HBV DNA, and drug-specific renal/bone safety. HBV DNA is commonly checked every 3 months until suppressed and every 3–6 months thereafter. Continue HCC surveillance when indicated.
After HBsAg lossConfirm the result and anti-HBs status. Continue HCC surveillance for cirrhosis, family history of HCC, men losing HBsAg after age 40, and women losing HBsAg after age 50.
After nucleos(t)ide analogue withdrawalThis is a specialist decision. If stopped, check ALT and HBV DNA every 1–3 months for 6 months, every 3 months for the next 6–12 months, then every 3–6 months.
Stopping therapy is not routine. The 2025 AASLD guideline suggests that HBeAg-negative adults without cirrhosis remain on nucleos(t)ide therapy until HBsAg loss. Do not withdraw suppressive therapy solely because HBV DNA becomes undetectable in a patient with current or prior cirrhosis. See the selected withdrawal criteria below.

6. HBV reactivation during immunosuppression

RESIDENT

HBV screening before immunosuppression uses HBsAg, total anti-HBc, and anti-HBs. A positive HBsAg or anti-HBc result makes baseline ALT and HBV DNA relevant to the prevention plan. Urgent cancer therapy should not be delayed while the evaluation is completed.

Risk is the combination of serostatus and the planned therapy

HIGH means an estimated reactivation risk greater than 10%. MODERATE means 1–10%. LOW means less than 1%. These estimates generally assume a single agent. Combination chemotherapy, added corticosteroids, detectable baseline HBV DNA, and prolonged treatment can increase risk.

ExposureHBsAg positiveHBsAg negative / anti-HBc positive
Anti-CD20 or other B-cell depletion, including rituximab and obinutuzumabHIGHHIGH
Hematopoietic stem-cell transplantationHIGHHIGH in cancer guidance; prophylaxis is generally indicated
CAR-T therapyHIGHMODERATE by AGA single-exposure estimates, but prophylaxis is generally used because of prior B-cell depletion and prolonged immune dysfunction
AnthracyclinesHIGHMODERATE
Anti-TNF therapyHIGHLOW
Immune-checkpoint inhibitors, including PD-1, PD-L1, and CTLA-4 inhibitorsMODERATELOW
Anti-T-cell therapy such as abataceptMODERATEMODERATE
Tyrosine-kinase inhibitorsHIGHMODERATE
Cytokine or integrin inhibitors such as ustekinumab or secukinumabHIGHMODERATE
IL-6 inhibitors and JAK inhibitorsHIGH under AGA 2025MODERATE under AGA 2025
Prednisone 10–20 mg/day or >20 mg/day for at least 4 weeksHIGHMODERATE
Prednisone <10 mg/day for at least 4 weeksMODERATELOW
A single systemic corticosteroid course of 1 week or less, or intra-articular steroidLOWLOW
Methotrexate, azathioprine, or 6-mercaptopurine aloneLOWLOW
HCV direct-acting antiviral therapy. See the DAA-specific prevention and monitoring pathway.HIGHLOW
Transarterial chemoembolization for HCCHIGHMODERATE
Do not overread the table. For HBsAg-positive patients receiving systemic anticancer therapy, ASCO recommends prophylaxis; hormonal therapy alone is the exception and follows usual HBV treatment criteria. Added corticosteroids or other systemic agents change that assessment. For resolved HBV, prophylaxis is the preferred approach with anti-CD20 therapy or stem-cell transplantation. With CAR-T, AGA favors prophylaxis at moderate risk; prior B-cell depletion and prolonged immune dysfunction further support that choice.
Risk groupPrevention strategy
HIGHHigh-barrier antiviral prophylaxis is strongly supported; entecavir, TAF, and TDF are usual options selected for the individual patient. It begins before or at immunosuppression. The cancer-guidance monitoring alternative below is limited to selected patients with past HBV receiving anti-CD20 therapy or stem-cell transplantation, with dependable testing and immediate treatment access.
MODERATEProphylaxis is generally favored. Active monitoring can be a reasonable alternative when the patient prioritizes avoiding antiviral burden and reliable ALT plus HBV DNA testing every 1–3 months is feasible.
LOWSurveillance is generally favored over routine prophylaxis. During ongoing immunosuppression, ALT plus HBV DNA every 1–3 months is a monitoring approach; HBsAg also helps detect reactivation in resolved infection. DAA-only exposure has a separate HCV monitoring pathway.
All HBV markers negativeReview the vaccination record and vaccinate if susceptible. Vaccination does not provide immediate protection and does not replace prophylaxis for someone with prior infection.

For selected patients with past HBV receiving anti-CD20 therapy or transplantation, ASCO allows an alternative of HBsAg and HBV DNA every 3 months during treatment and for up to 12 months afterward, with treatment at the earliest reactivation. This requires sustained follow-up and specialist agreement; anti-HBs positivity alone does not justify choosing it.

When prophylaxis is used
For immunosuppressive therapy, prophylaxis spans immunosuppression and immune recovery. It begins before or at treatment and generally continues for at least 6 months after immunosuppression ends, or at least 12 months after B-cell depletion. In chronic HBV receiving systemic anticancer therapy, the cancer-specific guidance uses at least 12 months after the last anticancer treatment. CAR-T and stem-cell transplantation can require longer prophylaxis and monitoring because immune recovery is delayed.
When monitoring is used
ALT alone is inadequate. Active surveillance includes HBV DNA at 1–3 month intervals, with prompt high-barrier antiviral treatment if reactivation occurs.

The categories above follow the 2025 AGA framework, with ASCO cancer-specific guidance layered on top. The AGA categories for IL-6 and JAK inhibitors have low-certainty baseline estimates. Assess the specific agent, HBV DNA and concomitant immunosuppression; categories can differ between guidelines. Confirm current guidance when the planned regimen is new, combined, or prolonged.

7. Hepatitis C diagnosis, treatment eligibility, and cure

RESIDENT

Diagnosis

  • CDC recommends HCV screening at least once for adults aged 18 or older and during each pregnancy, except in settings with HCV RNA prevalence below 0.1%. Screen with HCV antibody and automatic reflex quantitative HCV RNA. Ongoing exposures can require repeat testing.
  • A positive antibody with negative RNA means no current viremia. It may represent resolved infection, successful prior treatment, or a false-positive antibody. Antibody usually remains positive after cure.
  • If exposure was recent, the patient is immunocompromised, or acute HCV is strongly suspected, order HCV RNA even when antibody is negative.
  • Confirmed acute HCV with quantifiable viremia is an indication for treatment without waiting for spontaneous clearance. The same regimens used for chronic infection apply. Mavyret gained an FDA indication for acute HCV in 2025; Epclusa use for acute infection remains guideline-supported off-label treatment.

Pretreatment checklist

Confirm infection. Quantitative HCV RNA. Genotype is unnecessary for most noncirrhotic treatment-naive patients receiving a pangenotypic regimen, but it remains relevant in selected cirrhosis and retreatment pathways.
Stage fibrosis. Calculate FIB-4. Review platelets and imaging; use elastography when needed. Presume cirrhosis when FIB-4 is >3.25 or there is prior elastography, biopsy, imaging, or clinical evidence of cirrhosis.
Obtain baseline laboratories. For the noncirrhotic simplified pathway, obtain CBC, hepatic panel, and eGFR within 6 months. For compensated cirrhosis, obtain those tests plus INR within 3 months and liver ultrasound within 6 months to exclude HCC and subclinical ascites. Assess Child-Pugh class and any prior decompensation before an NS3 protease inhibitor.
Check coinfections, pregnancy, and vaccines. HIV Ag/Ab and the complete HBV triple panel. Offer pregnancy testing and counseling about treatment risks when pregnancy is possible. Vaccinate against HAV and HBV when nonimmune.
Review every medication. Include OTC products and supplements. Check a current interaction resource. Pay particular attention to acid suppression, anticonvulsants, rifamycins, statins, amiodarone, anticoagulants, and antiretrovirals.

Simplified treatment for treatment-naive adults without cirrhosis

RegimenBrand nameCourse in this pathwaySelection and safety
Glecaprevir/pibrentasvirMavyret8 weeksA pangenotypic option taken with food. Its NS3 protease inhibitor component excludes patients with current or prior hepatic decompensation; the label also contraindicates Child-Pugh B/C disease.
Sofosbuvir/velpatasvirEpclusa12 weeksA pangenotypic option without a protease inhibitor. Acid suppression can reduce velpatasvir exposure. Coadministration with amiodarone is not recommended because serious symptomatic bradycardia has occurred with sofosbuvir-containing therapy.
Common HCV brand crosswalk: glecaprevir/pibrentasvir is Mavyret; sofosbuvir/velpatasvir is Epclusa; ledipasvir/sofosbuvir is Harvoni; sofosbuvir/velpatasvir/voxilaprevir is Vosevi; and elbasvir/grazoprevir is Zepatier. Mavyret and Vosevi contain protease inhibitors.

Simplified treatment excludes prior HCV treatment, HBsAg positivity, current pregnancy, known or suspected HCC, and prior liver transplantation. HIV coinfection with TDF use and eGFR <60 mL/min/1.73 m² requires additional monitoring outside simplified care. The separate compensated-cirrhosis pathway also excludes any prior decompensation and eGFR <30. For eligible Child-Pugh A patients, the options are an 8-week course of glecaprevir/pibrentasvir or a 12-week course of sofosbuvir/velpatasvir. The latter requires baseline NS5A resistance testing in genotype 3; Y93H changes the treatment pathway.

Severe renal impairment, including dialysis, does not by itself exclude either regimen under its label; an exclusion from simplified care is different from a drug contraindication. The Epclusa label has no safety data for the combination of decompensated cirrhosis and severe renal impairment or dialysis. Mavyret is contraindicated with rifampin or atazanavir. Proton-pump inhibitors are generally not recommended with Epclusa because they lower velpatasvir exposure. The limited labeled omeprazole exception depends on dose, food, and timing and cannot be generalized to other acid-suppressant regimens.

No protease inhibitor in decompensated cirrhosis. Glecaprevir in Mavyret, grazoprevir in Zepatier, and voxilaprevir in Vosevi must not be used with current or prior hepatic decompensation or Child-Pugh B/C disease. These patients follow a specialist pathway using a regimen without an NS3 protease inhibitor, with transplant assessment when appropriate.

Monitoring and follow-up

  • For uncomplicated noncirrhotic simplified therapy, routine on-treatment laboratory monitoring is usually unnecessary. In cirrhosis, consider hepatic tests and promptly evaluate jaundice, ascites, encephalopathy, or worsening laboratory results. Check in for adherence, new medications, and adverse effects.
  • Monitor glucose more closely in patients taking diabetes medications and INR in those taking warfarin because control may change as HCV clears.
  • Quantitative HCV RNA and a hepatic panel at least 12 weeks after treatment are the standard follow-up in the simplified pathway. Undetectable or unquantifiable HCV RNA documents SVR12. The monitoring guidance also allows consideration of HCV RNA at week 4 as an alternative measure of cure in patients without cirrhosis and without prior DAA exposure, particularly when completing SVR12 follow-up may be difficult.
  • After SVR, noncirrhotic patients need no HCV-specific liver follow-up unless liver tests remain abnormal or another liver disease is present.
  • With ongoing exposure risk, check HCV RNA, not antibody, at least annually and whenever unexplained liver-test abnormalities occur.
  • After HCV cure, patients with cirrhosis who remain candidates for HCC-directed treatment need continued surveillance. The AASLD HCC guidance recommends ultrasound plus AFP approximately every 6 months; use specialist-selected imaging when ultrasound quality is inadequate. Continue assessment of portal-hypertension risk.
FELLOW HBV during HCV treatment: test the HBV triple panel before DAAs. If HBsAg is positive, check HBV DNA before DAAs. When HBV treatment criteria are met, begin HBV therapy before or with the DAAs. The 2025 AGA reactivation guideline classifies HBsAg-positive patients receiving HCV DAAs as high risk and favors prophylaxis. AASLD-IDSA HCV Guidance also permits monthly HBV DNA monitoring during and immediately after DAA therapy when baseline HBV DNA is low or undetectable and ordinary HBV treatment criteria are not met. If monitoring is chosen, start HBV treatment for an increase in HBV DNA greater than tenfold above baseline, or a level above 1,000 IU/mL when baseline DNA was undetectable or unquantifiable. If prophylaxis is chosen, AASLD-IDSA HCV Guidance continues it through 12 weeks after DAA completion. In its DAA-specific discussion, AGA considers 6–12 months after DAA completion reasonable in selected patients, using clinical judgment and patient preference. These are prophylaxis approaches for patients who do not otherwise meet HBV treatment criteria. For HBsAg-negative, anti-HBc-positive patients receiving DAAs alone, HCV Guidance does not establish a routine HBV DNA schedule; unexplained ALT elevation during or after therapy should prompt assessment for reactivation, including HBV DNA and HBsAg.

8. Cases for the core lecture

Case 1: The positive core antibody

A patient scheduled for rituximab has HBsAg negative, total anti-HBc positive, and anti-HBs 42 mIU/mL.

Discussion: This serology represents resolved HBV. Anti-HBs does not remove the reactivation risk from rituximab. Baseline ALT and HBV DNA inform the plan, and high-barrier antiviral prophylaxis with entecavir, TAF, or TDF is the preferred prevention strategy. The usual minimum extends through 12 months after the final B-cell-depleting dose, with monitoring after prophylaxis ends.

Case 2: Normal ALT, very high DNA

A 44-year-old man is HBeAg positive, HBV DNA 18 million IU/mL, ALT 31 U/L on repeated measurements over at least 6 months, and has no cirrhosis by elastography.

Discussion: Normal ALT does not settle treatment eligibility. His repeated measurements fit an immune-tolerant laboratory pattern, but age over 40 places him in a group for whom the 2025 guidance conditionally supports treatment. Fibrosis, HCC risk, transmission concerns, and patient preference inform that decision; the evidence is very low certainty.

Case 3: HCV antibody positive, RNA negative

The patient has no recent exposure and normal liver tests.

Answer: There is no active HCV infection and no DAA indication. Determine whether this reflects prior cure, spontaneous clearance, or a false-positive antibody. Repeat RNA only if recent exposure, ongoing risk, immunosuppression, or unexplained hepatitis makes current infection plausible.

Case 4: HCV with prior ascites

A treatment-naive patient with HCV RNA positivity had documented ascites due to cirrhosis two years ago but now has normal bilirubin and albumin.

Discussion: Documented cirrhotic ascites represents prior hepatic decompensation. It excludes glecaprevir/pibrentasvir even when current liver tests and Child-Pugh classification have improved. This patient needs a specialist HCV pathway and assessment of the underlying liver disease.

9. Advanced fellow section

FELLOW OPTIONAL

Isolated anti-HBc: do not force one interpretation

PossibilityCluesReasonable next step
Remote resolved infection with waned anti-HBsPrior risk, birth in an endemic region, old positive resultsDocument reactivation risk. HBV DNA before significant immunosuppression.
False-positive anti-HBcLow pretest probability, no risk history, inconsistent repeat resultRepeat anti-HBc using the same assay to confirm a low-risk isolated result, as CDC recommends; obtain a new specimen and consult the laboratory if discordance persists. Vaccinate if susceptible.
Window-period acute HBVRecent exposure, abrupt hepatitis, IgM anti-HBc positiveRepeat HBsAg/anti-HBs, obtain HBV DNA, and follow ALT/INR.
Occult HBVHBsAg negative with detectable HBV DNA, especially during immunosuppression or unexplained hepatitisConfirm HBV DNA and manage according to clinical setting and reactivation risk.
A vaccine challenge is not a definitive diagnostic test for isolated anti-HBc. An anamnestic response can support prior immunity, but a response does not erase documented anti-HBc or remove future reactivation risk.

Discordant or indeterminate HBV findings

  • New weak HBsAg positivity after vaccination: repeat after the period of possible transient antigenemia and obtain total anti-HBc/HBV DNA if current infection remains plausible.
  • HBsAg and anti-HBs both positive: confirm results and obtain HBV DNA. Consider assay interference or passive antibody. Subtype-mismatched antibodies and surface-gene variants are reported explanations for coexistence; serology alone cannot identify the mechanism.
  • IgM anti-HBc positive in known chronic HBV: assess for flare/reactivation. Do not label acute infection without timing, prior serology, HBV DNA trajectory, and clinical context.
  • ALT high with HBV DNA <2,000: evaluate steatotic liver disease, alcohol, medications, HCV/HDV, autoimmune hepatitis, ischemia, and other causes. Continue serial HBV assessment because phase transition remains possible.
  • HBV DNA high with unexpectedly negative HBsAg: repeat both assays and consider occult infection or an HBsAg escape variant.

Immunosuppression: where mistakes occur

  • Ordering only HBsAg misses resolved infection and leaves patients with prior HBV unrecognized before rituximab or CAR-T therapy.
  • Using anti-HBs positivity as permission to skip prophylaxis with B-cell depletion is incorrect.
  • “Monitor liver enzymes” is not an adequate preemptive plan. HBV DNA must be included every 1–3 months, and the ordering clinician must own the results.
  • Stopping prophylaxis when chemotherapy ends ignores delayed reactivation, especially after B-cell depletion, CAR-T therapy, or transplantation.
  • New immunotherapies should be checked against current guidance. Checkpoint inhibitors can also cause immune-mediated hepatitis, so ALT elevation requires evaluation for both drug toxicity and HBV reactivation.

Stopping chronic HBV therapy

For HBeAg-negative adults, the 2025 guidance conditionally favors nucleos(t)ide therapy until HBsAg loss. Selected withdrawal is a specialist shared decision with very-low-certainty evidence. The proposed eligibility criteria exclude advanced fibrosis/cirrhosis, previous decompensation, HCC, extrahepatic HBV disease, HIV, and HDV. Other prerequisites include sustained undetectable HBV DNA, quantitative HBsAg <100 IU/mL, and dependable follow-up; if initially HBeAg positive, HBeAg loss with anti-HBe positivity must have persisted for at least 1 year. The guideline text and its algorithm differ on a minimum of 2 versus 3 years of suppression, and the evidence question also required at least 3 years of nucleos(t)ide therapy. That inconsistency prevents using the shortest interval as an automatic stopping rule.

The withdrawal monitoring schedule above is part of this specialist pathway. The guideline text calls for immediate restart if HBV DNA is ≥10,000 IU/mL regardless of ALT, ALT is ≥5 times ULN regardless of DNA, bilirubin is >2.5 mg/dL, or hepatic decompensation develops. Restart may also be appropriate for ordinary treatment indications, extrahepatic disease, or patient preference.

October 2026 HBV update: bepirovirsen

FDA approved bepirovirsen (Hibsago) on October 20, 2026, after the AASLD guideline. It is added to nucleos(t)ide therapy in selected noncirrhotic adults treated for at least 6 months, with suppressed HBV DNA and HBsAg ≤3,000 IU/mL by an FDA-authorized test. Specialist selection and dependable laboratory access are essential.

The FDA label separates a maximum 24-week bepirovirsen course from the subsequent period of nucleos(t)ide therapy, which continues for at least 24 additional weeks. Completion of injections alone does not justify stopping the background antiviral. The selected withdrawal population is HBeAg negative, with HBV DNA below quantification (<20 IU/mL), undetectable HBsAg at the labeled assay sensitivity (limit of detection 0.05 IU/mL), ALT ≤2 times ULN, and no continuing need for nucleos(t)ide therapy to treat HIV. Close laboratory and clinical follow-up continues for at least 1 year after nucleos(t)ide cessation. HBV-directed withdrawal must not interrupt effective HIV treatment.

Contraindications include acute hepatic impairment, cirrhosis, and baseline platelets <100 × 109/L. Boxed warnings concern hepatic flares and thrombocytopenia. Baseline assessment includes HBV markers, hepatic tests, platelets, eGFR, and urine albumin-to-creatinine ratio. Minimum on-treatment monitoring is platelets weekly, ALT/bilirubin weekly through week 12 then every other week, and eGFR every other week through week 24. Abnormal results change testing frequency and can require interruption or permanent discontinuation under the label.

No dose adjustment is recommended for mild renal impairment; safety data are insufficient in moderate/severe renal impairment, pregnancy, and HCV coinfection. HDV coinfection and concomitant peginterferon are not recommended. Review anticoagulants, antiplatelets, platelet-lowering drugs, and nephrotoxic drugs. Hold treatment and obtain platelets promptly for new bleeding; unexplained immune-mediated toxicity requires permanent discontinuation. This is a distinct labeled pathway, not permission for routine antiviral withdrawal.

HCV situations outside simplified treatment

SituationWhy it changes management
Prior DAA exposureRegimen history, genotype, cirrhosis, resistance context, and prior failure determine retreatment. Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) is a common salvage backbone, but it contains a protease inhibitor and is not for decompensated cirrhosis.
Decompensated cirrhosisNS3 protease inhibitors are excluded. In patients without prior sofosbuvir/NS5A treatment failure, sofosbuvir/velpatasvir is paired with ribavirin for a 12-week course when ribavirin is suitable, or used for 24 weeks without it when ribavirin is unsuitable. The ribavirin-free 24-week course is guideline-supported off-label use. Prior sofosbuvir/NS5A failure changes the pathway, generally to 24 weeks with ribavirin under specialist care, based on lower-certainty evidence.
Ribavirin eligibilityAssess renal function, hemoglobin, cardiac disease, pregnancy risk, hemoglobinopathies, and interacting drugs. It is contraindicated during pregnancy, when a male patient’s partner is pregnant, with hemoglobinopathies, and with didanosine. Avoid it with significant or unstable cardiac disease. Use product-specific renal dosing and pregnancy-prevention instructions; monitor hemoglobin before treatment, at weeks 2 and 4, and thereafter as indicated. Child-Pugh C patients generally start at a reduced ribavirin dose in the specialist pathway.
HBsAg positiveConcurrent HBV requires a separate treatment or reactivation-prevention plan.
PregnancyRoutine DAA treatment during pregnancy is not yet a standard simplified pathway; individualize with maternal-fetal medicine and hepatology/ID.
Solid-organ transplant, HCC, or severe renal complexityDrug interactions, graft status, cancer timing, and regimen-specific evidence require specialist selection.
Persistent ALT elevation after SVRSVR does not explain ongoing hepatitis. Evaluate alcohol, MASLD, HBV, autoimmune disease, iron overload, medications, and other causes.

10. Selected references and tools

  1. Ghany MG, et al. AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B. Published online November 4, 2025; final publication, Hepatology. 2026;83:974–997. Figure 5 and Table 4 accessed October 31, 2026.
  2. Terrault NA, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67:1560–1599. Apply the 2025 update where recommendations changed.
  3. Centers for Disease Control and Prevention. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations, United States, 2023.
  4. CDC. Clinical Screening and Diagnosis for Hepatitis C.
  5. Ali FS, et al. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. 2025;168:267–284. See Tables 4 and 6 and the HCV direct-acting antiviral subsection.
  6. ASCO. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: Provisional Clinical Opinion Update. J Clin Oncol. 2020.
  7. AASLD-IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Living guidance; HBV-reactivation monitoring pathway accessed October 31, 2026. See monitoring during and after HCV therapy.
  8. University of Liverpool. Hepatitis Drug Interactions Checker.
  9. Singal AG, et al. AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. Hepatology. 2023. Surveillance statements 7–12; the 2025 critical update concerns adjuvant HCC treatment.
  10. AASLD-IDSA HCV Guidance. Simplified treatment without cirrhosis; compensated cirrhosis; decompensated cirrhosis; acute HCV; pregnancy.
  11. Current prescribing information. Mavyret; Epclusa; Vosevi; ribavirin tablets. Product labels differ for some renal and pregnancy-prevention instructions.
  12. CDC. Clinical overview of perinatal hepatitis B.

The source links provide the detailed eligibility criteria, prescribing information, and follow-up pathways discussed in this module.